SABS - SAB Biotherapeutics, Inc.

3.52
-0.280   -7.955%

Share volume: 555,970
Last Updated: 04-24-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.22%

PREVIOUS CLOSE
CHG
CHG%
$3.80
-0.28
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 36%
Dept financing 24%
Liquidity 58%
Performance 35%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-11.78%
1 Month
-8.57%
3 Months
-17.76%
6 Months
16.17%
1 Year
96.66%
2 Year
-15.99%
Key data
Stock price
$3.52
P/E Ratio 
N/A
DAY RANGE
$3.51 - $3.75
EPS 
-$1.72
52 WEEK RANGE
$1.53 - $6.60
52 WEEK CHANGE
$96.66
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
50.951 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-19-2025
BETA 
-0.16
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$413,746
AVERAGE 30 VOLUME 
$424,196
Company detail
CEO: Eddie J. Sullivan
Region: US
Website: sabbiotherapeutics.com
Employees: 140
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

SAB Biotherapeutics, Inc. engages in the development of immunotherapies based on human antibodies. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Recent news